Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 7Gastrointestinal 7Breast 6Gynecologic 3CNS 3Thoracic 2Plasma cell 2Other 2Lymphoid 2Dermatologic 2Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Overweight 1Ovarian Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fatigue 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diet Therapy × Lymphoid × 1 year × Clear all
NCT02194387 2026-03-09

Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

M.D. Anderson Cancer Center

Phase NA Active not recruiting
337 enrolled
BreastGastrointestinalGynecologicLymphoidOther hematologic neoplasm

Breast Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Fatigue, Ovarian Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Overweight

NCT06785324 2025-06-19

NEOMA ALL

University of Chicago

Phase NA Recruiting
20 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡